MTMR7 and neoplasm: MTMR7 was lost to a higher percentage in tumor tissues of both patient groups (T2DM: 88%, 15 of 17; IGF2 LOI: 92%, 12 of 13) than in individuals with neither T2DM nor IGF2 LOI (44%, 7 of 16) (Figure 4B).